Cathie Wood and Ark Invest have significantly increased their stake in Tempus AI, with the innovation-focused investment firm acquiring over 600,000 shares across its funds since the start of 2025.
Ark Invest's interest in TEM began on December 6, when the ARK Genomic Revolution ETF made its initial purchase of shares in the healthcare technology company. Since then, Tempus AI has rapidly ascended within Ark's portfolio, becoming the tenth largest holding in the flagship ARK Innovation ETF . TEM now represents 3.2% of ARKK's total assets, with a market value exceeding $265 million.
Additionally, Tempus is the fourth-largest position in the ARK Genomic Revolution ETF, accounting for 5.64% of the fund's portfolio, with a market value nearing $68 million.
In January 2025, Ark Innovation ETF expanded its position in TEM, acquiring 439,536 shares, while ARKG also increased its holdings, purchasing an additional 179,255 shares during the same period.
Tempus AI is currently up 62% year-to-date.
In 2025, Wood’s ARKK is up by 10% and ARKG is up on the year by 17%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。